Spark Therapeutics, Inc. Common Stock
ONCE
ONCE was delisted on the 16th of December, 2019.
105 hedge funds and large institutions have $575M invested in Spark Therapeutics, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 48 increasing their positions, 25 reducing their positions, and 12 closing their positions.
92% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 25
25% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 12
3% more funds holding
Funds holding: 102 → 105 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
32% less capital invested
Capital invested by funds: $845M → $575M (-$270M)
78% less call options, than puts
Call options by funds: $1.65M | Put options by funds: $7.42M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.5M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$6.34M |
| 3 |
RIM
RS Investment Management
San Francisco,
California
|
+$2.78M |
| 4 |
JP Morgan Chase
New York
|
+$2.73M |
| 5 |
Axa
Paris,
France
|
+$2.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$7.56M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$4.73M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$2.14M |
| 4 |
D.E. Shaw & Co
New York
|
-$2M |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$1.93M |
ONCE Hedge Fund Activity: Q1 2016 in Review
105 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics, Inc. Common Stock (ONCE) for Q1 2016, worth a combined $575M — down 32% from $845M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ONCE positions and 12 closed out — a net gain of 3 holders — while 48 added to existing stakes and 25 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $14.5M. The largest seller was Lord, Abbett & Co, cutting an estimated $7.56M.
- 105 institutional investors held Spark Therapeutics, Inc. Common Stock (ONCE) as of Q1 2016, up from 102 in Q4 2015.
- Funds reported $575M of Spark Therapeutics, Inc. Common Stock stock for Q1 2016, down 32% quarter-over-quarter.
- 15 funds opened new Spark Therapeutics, Inc. Common Stock positions in Q1 2016 and 12 closed out, a net change of +3 holders.
- The largest Spark Therapeutics, Inc. Common Stock buyer in Q1 2016 was T. Rowe Price Associates, an estimated $14.5M added.
- The largest Spark Therapeutics, Inc. Common Stock seller in Q1 2016 was Lord, Abbett & Co, an estimated $7.56M sold.
Based on aggregated 13F filings for Q1 2016.